دورية أكاديمية
Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae.
| العنوان: | Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae. |
|---|---|
| المؤلفون: | Euba B; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, CIBERES, Madrid, Spain Instituto de Agrobiotecnología, CSIC-Universidad Pública Navarra-Gobierno Navarra, Mutilva, Spain., Moleres J; Instituto de Agrobiotecnología, CSIC-Universidad Pública Navarra-Gobierno Navarra, Mutilva, Spain., Segura V; Centro Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain., Viadas C; Instituto de Agrobiotecnología, CSIC-Universidad Pública Navarra-Gobierno Navarra, Mutilva, Spain., Morey P; Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany., Moranta D; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, CIBERES, Madrid, Spain Programme Infection and Immunity, Fundación de Investigación Sanitaria de las Islas Baleares-Instituto de Investigación Sanitaria de Palma, Mallorca, Spain., Leiva J; Servicio de Microbiología, Clínica Univesidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., de-Torres JP; Servicio de Neumología, Clínica Universidad de Navarra, Pamplona, Spain., Bengoechea JA; Centre for Infection and Immunity, Queen's University, Belfast, United Kingdom Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Garmendia J; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, CIBERES, Madrid, Spain Instituto de Agrobiotecnología, CSIC-Universidad Pública Navarra-Gobierno Navarra, Mutilva, Spain juncal.garmendia@unavarra.es. |
| المصدر: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Dec; Vol. 59 (12), pp. 7581-92. Date of Electronic Publication: 2015 Sep 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology |
| مواضيع طبية MeSH: | Anti-Bacterial Agents/*pharmacology , Cyclic Nucleotide Phosphodiesterases, Type 4/*genetics , Haemophilus Infections/*drug therapy , Phosphodiesterase 4 Inhibitors/*pharmacology , Rolipram/*pharmacology , Sirtuin 1/*genetics , Stilbenes/*pharmacology, Animals ; Cell Line, Tumor ; Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism ; Drug Therapy, Combination ; Enzyme Activation/drug effects ; Epithelial Cells/drug effects ; Epithelial Cells/microbiology ; Epithelial Cells/pathology ; Gene Expression Profiling ; Gene Expression Regulation ; Genome, Human ; Haemophilus Infections/genetics ; Haemophilus Infections/microbiology ; Haemophilus Infections/pathology ; Haemophilus influenzae/drug effects ; Haemophilus influenzae/physiology ; Host-Pathogen Interactions ; Humans ; Lung/drug effects ; Lung/microbiology ; Lung/pathology ; Mice ; Respiratory Mucosa/drug effects ; Respiratory Mucosa/microbiology ; Respiratory Mucosa/pathology ; Resveratrol ; Signal Transduction ; Sirtuin 1/metabolism |
| مستخلص: | Therapies that are safe, effective, and not vulnerable to developing resistance are highly desirable to counteract bacterial infections. Host-directed therapeutics is an antimicrobial approach alternative to conventional antibiotics based on perturbing host pathways subverted by pathogens during their life cycle by using host-directed drugs. In this study, we identified and evaluated the efficacy of a panel of host-directed drugs against respiratory infection by nontypeable Haemophilus influenzae (NTHi). NTHi is an opportunistic pathogen that is an important cause of exacerbation of chronic obstructive pulmonary disease (COPD). We screened for host genes differentially expressed upon infection by the clinical isolate NTHi375 by analyzing cell whole-genome expression profiling and identified a repertoire of host target candidates that were pharmacologically modulated. Based on the proposed relationship between NTHi intracellular location and persistence, we hypothesized that drugs perturbing host pathways used by NTHi to enter epithelial cells could have antimicrobial potential against NTHi infection. Interfering drugs were tested for their effects on bacterial and cellular viability, on NTHi-epithelial cell interplay, and on mouse pulmonary infection. Glucocorticoids and statins lacked in vitro and/or in vivo efficacy. Conversely, the sirtuin-1 activator resveratrol showed a bactericidal effect against NTHi, and the PDE4 inhibitor rolipram showed therapeutic efficacy by lowering NTHi375 counts intracellularly and in the lungs of infected mice. PDE4 inhibition is currently prescribed in COPD, and resveratrol is an attractive geroprotector for COPD treatment. Together, these results expand our knowledge of NTHi-triggered host subversion and frame the antimicrobial potential of rolipram and resveratrol against NTHi respiratory infection. (Copyright © 2015, American Society for Microbiology. All Rights Reserved.) |
| References: | Thorax. 2014 Oct;69(10):891-4. (PMID: 25015240) PLoS One. 2013;8(9):e73706. (PMID: 24040034) Curr Pharm Biotechnol. 2010 Dec;11(8):810-8. (PMID: 20874691) Int Microbiol. 2012 Dec;15(4):159-72. (PMID: 23844475) Am J Respir Crit Care Med. 2004 Aug 1;170(3):266-72. (PMID: 15117742) Am J Health Syst Pharm. 2013 Dec 1;70(23):2087-95. (PMID: 24249758) Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1800-9. (PMID: 25831493) PLoS One. 2014;9(5):e97020. (PMID: 24824990) MBio. 2014;5(4):e01534-14. (PMID: 25073644) FASEB J. 2009 Sep;23(9):2810-9. (PMID: 19376817) Biochem Biophys Res Commun. 2008 Dec 19;377(3):763-8. (PMID: 18957283) Trends Cardiovasc Med. 2015 Apr;25(3):216-25. (PMID: 25802224) Eur Respir J. 2010 Jul;36(1):178-86. (PMID: 19926732) FEMS Microbiol Lett. 2012 Jul;332(1):1-9. (PMID: 22471308) J Biol Chem. 2002 Dec 6;277(49):47444-50. (PMID: 12356755) N Engl J Med. 2014 Jun 5;370(23):2201-10. (PMID: 24836125) Cancer Prev Res (Phila). 2012 May;5(5):788-97. (PMID: 22562408) Infect Immun. 2014 Jan;82(1):433-44. (PMID: 24218477) Mol Microbiol. 2000 Jul;37(1):13-27. (PMID: 10931302) Cell Microbiol. 2005 May;7(5):613-20. (PMID: 15839890) Am J Respir Cell Mol Biol. 2002 May;26(5):602-9. (PMID: 11970913) Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9090-5. (PMID: 8799159) Am J Respir Crit Care Med. 2009 Apr 15;179(8):666-75. (PMID: 19179487) J Environ Pathol Toxicol Oncol. 2003;22(2):75-92. (PMID: 14533871) Nat Commun. 2015;6:6062. (PMID: 25585690) J Clin Invest. 2012 Jun;122(6):2032-45. (PMID: 22546858) EMBO Mol Med. 2015 Aug;7(8):1018-33. (PMID: 25995336) Microbiology. 2011 Jan;157(Pt 1):234-50. (PMID: 20929955) PLoS One. 2011;6(11):e28216. (PMID: 22132240) Paediatr Respir Rev. 2001 Mar;2(1):57-62. (PMID: 16263481) Stat Appl Genet Mol Biol. 2004;3:Article3. (PMID: 16646809) PLoS One. 2015;10(4):e0123154. (PMID: 25894755) Pharmacol Ther. 2006 Jan;109(1-2):238-45. (PMID: 16171872) Antimicrob Agents Chemother. 2006 Jan;50(1):391-5. (PMID: 16377721) Trends Microbiol. 2013 Mar;21(3):111-3. (PMID: 23473628) Infect Immun. 1990 Dec;58(12):4036-44. (PMID: 2254028) PLoS Pathog. 2014 Feb;10(2):e1003946. (PMID: 24586159) Microbiology. 2012 Sep;158(Pt 9):2384-98. (PMID: 22723286) Trends Biochem Sci. 2010 Feb;35(2):91-100. (PMID: 19864144) Br J Pharmacol. 2003 Nov;140(5):855-62. (PMID: 14585803) Cell Mol Immunol. 2012 Mar;9(2):131-5. (PMID: 22307042) Infect Immun. 1999 Aug;67(8):4161-70. (PMID: 10417188) Antimicrob Agents Chemother. 2015 May;59(5):2700-12. (PMID: 25712355) Genome Announc. 2014 Dec 04;2(6):null. (PMID: 25477405) Environ Microbiol Rep. 2010 Apr;2(2):219-27. (PMID: 23766072) Pharmacol Ther. 2013 Feb;137(2):248-65. (PMID: 23089371) Nat Commun. 2013;4:1684. (PMID: 23575688) J Clin Microbiol. 2011 Nov;49(11):3728-32. (PMID: 21900515) Sci Signal. 2008;1(29):re8. (PMID: 18648074) Biochim Biophys Acta. 2004 May 3;1691(2-3):169-79. (PMID: 15110997) Drug Discov Today Technol. 2014 Mar;11:33-9. (PMID: 24847651) Front Cell Infect Microbiol. 2011;1:1. (PMID: 22919570) Eur Respir J. 2009 Jul;34(1):5-6. (PMID: 19567596) PLoS One. 2014;9(11):e112516. (PMID: 25389768) Respir Res. 2006;7:57. (PMID: 16595015) Int J Antimicrob Agents. 2013 May;41(5):477-9. (PMID: 23541304) Int J Chron Obstruct Pulmon Dis. 2012;7:641-52. (PMID: 23055713) Am J Respir Crit Care Med. 2007 Jul 15;176(2):162-6. (PMID: 17400730) Nutr Rev. 2008 Oct;66(10):591-6. (PMID: 18826454) J Antimicrob Chemother. 2008 Feb;61(2):362-4. (PMID: 18086693) Infect Immun. 1994 Feb;62(2):673-9. (PMID: 7507900) Eur Respir J. 1998 Jan;11(1):86-90. (PMID: 9543275) J Cell Sci. 2010 Dec 15;123(Pt 24):4280-91. (PMID: 21098633) Infect Immun. 2013 Nov;81(11):4100-11. (PMID: 23980106) Nat Rev Microbiol. 2012 Apr;10(4):243-54. (PMID: 22421877) J Biol Chem. 2002 May 10;277(19):17263-70. (PMID: 11867630) |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Phosphodiesterase 4 Inhibitors) 0 (Stilbenes) EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4) EC 3.5.1.- (Sirt1 protein, mouse) EC 3.5.1.- (Sirtuin 1) K676NL63N7 (Rolipram) Q369O8926L (Resveratrol) |
| تواريخ الأحداث: | Date Created: 20150930 Date Completed: 20160831 Latest Revision: 20181202 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC4649218 |
| DOI: | 10.1128/AAC.01278-15 |
| PMID: | 26416856 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-6596 |
|---|---|
| DOI: | 10.1128/AAC.01278-15 |